People · Operator

Harry L. Leider

Named in public records as an officer, director or promoter · active 2022–2022 · Pharmaceuticals

1
Companies
1
Filings
$576K
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Gelesis Holdings, Inc.PharmaceuticalsPre-Seed$576K$7.9M2022
Operator network

Harry L. Leider at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Clayton L. Christopher · 2 companies · 1 sharedClayton L. Christ…David Pass · 2 companies · 1 sharedDavid PassYishai Zohar · 2 companies · 1 sharedYishai ZoharAlessandro L. Sannino · 1 companies · 1 sharedAlessandro L. San…Alison L. Bauerlein · 1 companies · 1 sharedAlison L. Bauerle…David L. Abraham · 1 companies · 1 sharedDavid L. AbrahamDominic L. Perks · 1 companies · 1 sharedDominic L. PerksElaine L. Chiquette · 1 companies · 1 sharedElaine L. Chiquet…Elliot L. Maltz · 1 companies · 1 sharedElliot L. MaltzJane L. Wildman · 1 companies · 1 sharedJane L. WildmanKathryn L. Cavanaugh · 1 companies · 1 sharedKathryn L. Cavana…Paul L. Fonteyne · 1 companies · 1 sharedPaul L. FonteyneRaju L. Kucherlapati · 1 companies · 1 sharedRaju L. Kucherlap…Gelesis Holdings, Inc. · $0.6M raisedGelesis Holdings, Inc.Harry L. LeiderHL
Harry L. Leider Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Harry L. Leider on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Yishai Zohar12
Clayton L. Christopher12
David Pass12
Alison L. Bauerlein11
Jane L. Wildman11
Raju L. Kucherlapati11
Elaine L. Chiquette11
Dominic L. Perks11
Kathryn L. Cavanaugh11
Paul L. Fonteyne11
Elliot L. Maltz11
David L. Abraham11
Alessandro L. Sannino11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.